Market Alert : Global Markets Show Mixed Signals Amid Falling Oil Prices, Rising Bond Yields and Persistent US Inflation

Mayank Bansal
Mayank Bansal, CFA
Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.

3 ASX Stocks to Watch: AU$2.75 Takeover Proposal, Concentrate Prepayment and Wound-Care Study Results

3 ASX Stocks to Watch: AU$2.75 Takeover Proposal, Concentrate Prepayment and Wound-Care Study Results Source: Kapitales Research

Highlights:

  • A software company entered exclusivity talks on a AU$2.75 a share indicative cash proposal, a 73.0% premium to its last close.

  • A gold-antimony developer received a US$30 million prepayment from offtake partners while commissioning its mine.

  • A wound care company reported that its study met its primary endpoint, with median graft readiness of 11 days.

Three ASX-listed companies made notable announcements this week, covering a private equity takeover approach, fresh funding for a mine ramp-up and positive clinical data. Here is what each filing says.

Stocks in Focus

  • Nuix Limited (ASX: NXL) is currently trading at AU$2.310.

  • Larvotto Resources Limited (ASX: LRV) is currently trading at AU$0.735.

  • AVITA Medical, Inc. (ASX: AVH) is currently trading at AU$4.720.

Nuix Limited: Takeover Proposal, 18 November 2026

On 18 November 2026, Nuix said it had signed a process and exclusivity deed with US private equity firm Haveli, following an unsolicited, non-binding proposal of AU$2.75 cash per share. The price is a 73.0% premium to the 17 November close of AU$1.59 and follows earlier, lower proposals dating from July 2026. Exclusivity runs five weeks, with no break fee payable by Nuix. If a binding offer of at least AU$2.75 emerges, the board intends to recommend it, subject to conditions and an independent expert. Largest shareholder Macquarie, with about 28%, supports the process. Shareholders need take no action.

Larvotto Resources Limited: Prepayment, 18 November 2026

Larvotto announced on 18 November 2026 that offtake partners Glencore and Wogen Resources have each advanced US$15 million, a combined US$30 million, against future concentrate supply. The funds are available for 12 months and will be settled through deliveries of gold and antimony concentrate. They support working capital while the Hillgrove Mine in New South Wales completes commissioning by the end of December 2026. Gold concentrate deliveries have started, antimony shipments began in October, and first gold doré is expected in late November. Some money will fund tungsten testwork.

AVITA Medical, Inc.: Cohealyx Study Data, 16 November 2026

AVITA Medical released complete results from its Cohealyx I study on 16 November 2026 (US time). The trial met its primary endpoint, with mean time to graft readiness of 13.6 days against a 28-day performance goal, a median of 11 days, and 72% of wounds ready within two weeks. Eight weeks after grafting, 88% of assessed patients had healed. Scar scores improved from 5.2 to 3.5 between weeks 12 and 26, and no Cohealyx-related adverse events were reported. The study followed 40 patients and was funded by AVITA.

Final Thoughts

Together, these updates show how takeover interest, project funding and clinical evidence can shape investor attention. Investors should read the full announcements before making decisions. This article is general information only and is not financial advice.

Note: All data presented is based on information available at the time of writing.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au